Regencell Bioscience Holdings Limited (RGC) exhibited a high short interest of 1.82 million shares and 7.24 Days to Cover as of August 6, 2025, which can be attributed to several factors commonly observed in the market for early-stage bioscience companies.

Key factors likely contributing to this significant short interest include:

• Early-Stage and Unprofitable Business Model: Regencell Bioscience is an early-stage company focused on the research and development of Traditional Chinese Medicine (TCM) for neurocognitive disorders. As of December 31, 2024, the company reported negative operating income and net income, with a net loss of $4.09 million for the trailing twelve months. Unprofitable, speculative ventures often attract short sellers who anticipate challenges in commercialization and sustained losses.
• Extreme Price Appreciation: The stock experienced an extraordinary increase of 4,726.00% from August 7, 2024, to August 6, 2025, rising from $0.26 to $12.70 per share. Such a massive run-up in share price, particularly for a company without positive earnings, frequently draws in short sellers who believe the valuation has become detached from fundamental reality and is due for a correction.
• High Off-Exchange Short Volume: On August 6, 2025, the off-exchange short volume ratio for RGC was 64.53%. A high percentage of short volume occurring off-exchange can indicate concentrated shorting activity, potentially by sophisticated investors seeking to minimize market impact or exploit perceived overvaluation.
• Fluctuating Short Availability: Fintel data shows that short shares availability for RGC fluctuated on August 6, 2025, with periods of zero shares available for shorting, followed by increases. This scarcity can signal strong demand from short sellers, potentially driving up borrow fees, which would further indicate conviction in a downside move.

These elements collectively suggest that market participants are betting against RGC, likely due to concerns about its valuation relative to its current financial performance and the inherent risks associated with early-stage biotech development.

Analyze the historical short borrow fee rates for RGC leading up to August 6, 2025, to understand the cost of shorting.

Comment

Metadata

Author: AI Assistant Date: 2025-09-29

Content

Analyzing the historical short borrow fee rates for Regencell Bioscience Holdings Limited (RGC) leading up to August 6, 2025, reveals a significant cost associated with shorting the stock, which further underscores the conviction of short sellers.

Key observations regarding RGC's short borrow fee rates:

• Extremely High Borrow Rates: On August 6, 2025, the short borrow fee rates for RGC were exceptionally high, ranging from a minimum of 147.55% to a maximum of 176.76% on an annualized basis, with the latest reported rate at 152.65%.
• Consistent High Rates in Preceding Period: The days leading up to August 6 also showed consistently elevated borrow rates. For instance, on August 5, rates ranged from 149.51% to 181.04%, and on August 4, they saw a maximum of 194.26%. Throughout late July and early August 2025, the rates generally remained well above 130%, frequently exceeding 150%.
• Implication of High Fees: Such high borrow fees indicate a strong demand to short the stock coupled with limited supply of shares available for lending. This suggests that despite the substantial cost, short sellers perceive a significant downside potential in RGC, making the high fees an acceptable expense for their bearish bets. This level of borrow cost can also act as a catalyst for short squeezes if the stock price moves unexpectedly against short positions, as the cost of maintaining those positions becomes prohibitive.

The persistence of these high borrow rates highlights that the market's bearish sentiment on RGC is not only widespread but also deeply held, with short sellers willing to pay a premium to express their negative outlook.

Analyze the trend in RGC's short shares availability alongside borrow rates to understand the supply-demand dynamics for shorting the stock.